MedTrace Logo

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT07174726 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-02-19

No results posted yet for this study

Summary

The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.

Conditions

  • X-Linked Retinitis Pigmentosa (XLRP)

Interventions

BIOLOGICAL

Adeno-associated virus vector expressing a human RPGR gene

Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501

Sponsors & Collaborators

  • Beacon Therapeutics

    lead INDUSTRY

Principal Investigators

  • None None

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-10
Primary Completion
2027-06-30
Completion
2030-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07174726 on ClinicalTrials.gov